Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Personal Care Products
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 375422
6,626,858 – Shunt device and method for treating glaucoma
9,827,143 – Shunt device and method for treating ocular disorders
IPSCIO Record ID: 2942
Additionally, if the lawsuit is dismissed the Licensee will enter into another Agreement whereby they will have the right to continue to manufacture and market the product subject to the lawsuit.
IPSCIO Record ID: 26782
Licensor's primary products are the patented PresVIEW device and the related PresVIEW Incision System, the automated surgical instrument for the surgical treatment of Presbyopia, Ocular Hypertension and Primary Open Angle Glaucoma, or POA Glaucoma, in the human eye.
The PresVIEW device consists of four separate tiny plastic segments, each about the size of a grain of rice, made from polymethylacrylate, or PMMA. PMMA has been implanted in the eye for other types of surgical procedures (intraocular lenses, hard contact lenses) for over fifty years. The surgeon uses the PresVIEW Incision System to make four superficial incisions in the quadrants of the sclera (white of the eye). The PresVIEW device is inserted into the superficial tunnels, causing a lift in the sclera that in turn reduces the crowding of the underlying muscles.
The full royalty rate schedule has not been made public, the only publicly available rate is a know-how royalty rate for countries where a relevant patent has expired.
IPSCIO Record ID: 2991
IPSCIO Record ID: 6607
IPSCIO Record ID: 3011
On January 14, 2010, the licensee agreed to a Consent Judgment that it has infringed on the 6,206,873 patent and that the patent is valid and enforceable.
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 26276
This case was tried before a jury in the U.S. District Court from April 10, 2006 through April 28, 2006. After deliberations, on May 4, 2006, the jury rendered a verdict in favor of the Plaintiffs by finding that the NF-kB â€˜516 Claims asserted in the lawsuit are valid and infringed by Lilly through sales of Evista and Xigris in the United States. One defense regarding validity was not submitted to the jury and was instead the subject of a bench trial, as addressed below. The jury awarded damages to the Plaintiffs in the amount of approximately $65.2 million, based on the juryâ€™s determination of a reasonable royalty rate of 2.3% to be paid by Lilly to the Plaintiffs based on U.S. sales of Evista and Xigris from the date of the filing of the lawsuit on June 25, 2002 through February 28, 2006. The jury awarded further damages on an ongoing basis, in amounts to be determined, equal to 2.3% of U.S. sales of Evista and Xigris through the year 2019, when the patent expires. If the verdict is upheld, damages paid by Lilly will be applied first to reimburse us for any unreimbursed legal fees and expenses relating to the litigation. We will receive 91% of the remainder, and the co-plaintiffs will receive 9%.
The dispute involved licensor's U.S. patent covering methods of treating disease by regulating NF-kappa B cell-signaling activity, and jurors awarded damages to licensor and its co-plaintiffs. Licensee plans first to ask the judge to set aside the jury's verdict regarding Evista and Xigris and then to appeal, if necessary.
IPSCIO Record ID: 3489
And MaXcess instruments provide access to the spine in a manner that affords direct visualization and our nerve monitoring systems assist surgeons in avoiding critical nerves. Our MaXcess system consists of instrumentation and specialized implants that provide maximum access to the spine with minimal soft tissue disruption. MaXcess has a split blade design consisting of three blades that can be positioned to build the surgical exposure in the shape and size specific to the surgical requirements rather than the fixed tube design of other minimally invasive surgical systems. MaXcessâ€™ split blade design also provides expanded access to the spine, which allows surgeons to perform surgical procedures using instruments that are similar to those used in open procedures but with a significantly smaller incision. The ability to use familiar instruments reduces the learning curve and facilitates the adoption of our products. Our systemâ€™s illumination of the operative corridor aids in providing surgeons with direct visualization of the patientâ€™s anatomy, without the need for additional technology or other special equipment.